A hallmark of Parkinson's disease is the buildup of Lewy bodies—misfolded clumps of the protein known as alpha-synuclein.

An investigation by researchers from Case Western Reserve University School of Medicine in the US has filled in a missing link between the toxic build-up of proteins in the neurodegenerative condition ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...

Parkinson’s disease has long been defined by the slow, relentless loss of dopamine-producing neurons, with treatments focused ...

After three years of study, the researchers found that alpha-synuclein, a protein closely linked to Parkinson’s disease, ...

Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ ...

Amsterdam, July 22, 2024 – To date Parkinson's disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker ...

The study, conducted in mice and published in the Nature journal, identifies a key role of gut macrophages -- a specialised immune cell that kills pathogens -- in the transfer of toxic proteins from ...

“These are the first data to link ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in neurons of Parkinson’s disease patients,” said Stephen C. Glover, ZyVersa’s ...

Inspired by a creature from Greek mythology, researchers have created a ‘two-headed’ drug that prevents the production of the toxic protein linked to Parkinson’s disease before destroying the RNA ...